PDF
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
Organization: United States Centers for Disease Control (CDC)Published: 2022
"What is already known about this topic?
In preauthorization trials, adverse reactions were reported less frequently following a homologous COVID-19 mRNA vaccine booster dose than after receipt of the second primary dose.
What is added by this report?
Review of surveillance data found that local and systemic reactions were less frequent after a homologous COVID-19 mRNA vaccine booster dose than after the second primary vaccine dose. Myocarditis was rarely reported following an mRNA vaccine booster dose.
What are the implications for public health practice?
All persons aged ≥12 years should receive a COVID-19 booster dose. Vaccination providers should educate patients that local and systemic reactions are expected following a homologous COVID-19 mRNA vaccine booster; however, these reactions are less common than those following the second primary series dose." - Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
Product Type: Report
Category:
Vaccine Safety and Development,Vaccine Safety,Adverse Events Following Immunization (AEFI),Sub Topics: Vaccine Safety and Development,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Vaccine Monitoring and Surveillance,Vaccine Monitoring Vaccine Safety and DevelopmentVaccine Safety
Adverse Events Following Immunization (AEFI)
Sub Topics: Vaccine Safety and Development
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Vaccine Monitoring and Surveillance
Vaccine Monitoring
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.